Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer

Oncology

Volumn 80, Issue 1-2, 2011, Pages 97-101

  Isayama, Hiroyuki ^a   Nakai, Yousuke ^a   Yamamoto, Keisuke ^a   Sasaki, Takashi ^a   Mizuno, Suguru ^a   Yagioka, Hiroshi ^a   Yashima, Yoko ^a   Kawakubo, Kazumichi ^a   Kogure, Hirofumi ^a   Arizumi, Toshihiko ^a   Togawa, Osamu ^a   Ito, Yukiko ^a   Matsubara, Saburo ^a   Yamamoto, Natsuyo ^a   Sasahira, Naoki ^a   Hirano, Kenji ^a   Tsujino, Takeshi ^a   Tada, Minoru ^a   Omata, Masao ^b   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b YAMANASHI PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Chemotherapy; Gemcitabine; Oxaliplatin; Pancreatic cancer; Refractory

Indexed keywords

GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANOREXIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79958773387     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000328767     Document Type: Article

References (29)

1. Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413. (Pubitemid 27251144)
2. Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V: Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005; 6: 369-376. (Pubitemid 40753742)
3. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of canada clinical trials group. J Clin Oncol 2007; 25: 1960-1966. (Pubitemid 46972777)
4. Conroy T, Desseigne F, Ychou M, Ducreux M, Bouche O, Guimbaud R, Becouarn Y, Montoto-Grillot C, Gourgou-Bourgade S, Adenis A, Group. F-FP: Randomized phase III trial comparing folfirinox (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol 2010; 28: 4010.
5. Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P: Metaanalyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007; 25: 2607-2615. (Pubitemid 47041235)
6. Xie DR, Yang Q, Chen DL, Jiang ZM, Bi ZF, Ma W, Zhang YD: Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup metaanalyses of overall survival. Jpn J Clin Oncol 2010; 40: 432-441.
7. Heinemann V, Labianca R, Hinke A, Louvet C: Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the gercor/giscad intergroup study and a german multicenter study. Ann Oncol 2007; 18: 1652-1659. (Pubitemid 47514482)
8. Riess H PU, Stieler J, Schwaner I, Heil G, Görner M, Mölle M, Hilbig A, Dörken B, Oettle H: A randomized second line trial in patients with gemcitabine refractory advanced pancreatic cancer-CONKO 003. J Clin Oncol 2007; 25: 4517.
9. Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, Nakachi K, Najima M, Ogura T, Suzuki E: A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 2009; 63: 313-319.
10. Sudo K, Yamaguchi T, Nakamura K, Denda T, Hara T, Ishihara T, Yokosuka O: Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemother Pharmacol 2011; 67: 249-254.
11. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C: An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 2005; 68: 171-178. (Pubitemid 41158973)
12. Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S, Saito H: A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 2008; 61: 615-621.
13. Nakamura K, Yamaguchi T, Ishihara T, Kobayashi A, Tadenuma H, Sudo K, Kato H, Saisho H: Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 2005; 92: 2134-2139. (Pubitemid 40966247)
14. Ueno H, Okusaka T, Ikeda M, Ishiguro Y, Morizane C, Matsubara J, Furuse J, Ishii H, Nagase M, Nakachi K: A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology 2005; 69: 421-427. (Pubitemid 41797919)
15. Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H: Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 2006; 94: 1575-1579. (Pubitemid 43924916)
16. Kim MK, Lee KH, Jang BI, Kim TN, Eun JR, Bae SH, Ryoo HM, Lee SA, Hyun MS: S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer. Jpn J Clin Oncol 2009; 39: 49-53.
17. Lee GW, Kim HJ, Ju JH, Kim SH, Kim HG, Kim TH, Kim HJ, Jeong CY, Kang JH: Phase II trial of S-1 in combination with gemcitabine for chemo-naive patients with locally advanced or metastatic pancreatic cancer. Cancer Chemother Pharmacol 2009; 64: 707-713.
18. Nakai Y, Isayama H, Sasaki T, Sasahira N, Ito Y, Kogure H, Togawa O, Matsubara S, Arizumi T, Yagioka H, Yashima Y, Kawakubo K, Mizuno S, Yamamoto K, Hirano K, Tsujino T, Ijichi H, Toda N, Tada M, Kawabe T, Omata M: A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer. Oncology 2009; 77: 300-303.
19. Nakai Y, Isayama H, Sasaki T, Sasahira N, Ito Y, Kogure H, Togawa O, Matsubara S, Arizumi T, Yagioka H, Yashima Y, Kawakubo K, Mizuno S, Yamamoto K, Hirano K, Tsujino T, Ijichi H, Tateishi K, Toda N, Tada M, Omata M, Koike K: Impact of S-1 on the survival of patients with advanced pancreatic cancer. Pancreas 2010; 39: 989-993.
20. Nakai Y, Isayama H, Sasaki T, Sasahira N, Kogure H, Hirano K, Tsujino T, Ijichi H, Tateishi K, Tada M, Omata M, Koike K: Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in japan. Jpn J Clin Oncol 2010; 40: 774-780.
21. Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E, Hendlisz A, Van Laethem JL: Gemcitabine and oxaliplatin (gemox) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase ii study. Br J Cancer 2006; 94: 481-485. (Pubitemid 43289750)
22. Fortune BE, Li X, Kosuri KV, Weatherby LM, Thomas JP, Bekaii-Saab TS: Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study. Oncology 2009; 76: 333-337.
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. J Natl Cancer Inst 2000; 92: 205-216.
24. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson AB, 3rd: Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the eastern cooperative oncology group. J Clin Oncol 2009; 27: 3778-3785.
25. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E: Supraadditive effect of 2,2-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999; 44: 117-123. (Pubitemid 29297057)
26. Taieb J, Bonyhay L, Golli L, Ducreux M, Boleslawski E, Tigaud JM, de Baere T, Mansourbakht T, Delgado MA, Hannoun L, Poynard T, Boige V: Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 2003; 98: 2664-2670. (Pubitemid 37509531)
27. Li J, Merl M, Lee MX, Kaley K, Saif MW: Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience. Expert Opin Drug Saf 2010; 9: 207-213.
28. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27: 5513-5518.
29. Grothey A, Sargent D, Goldberg RM, Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214. (Pubitemid 41079833)